SAN FRANCISCO, July 7, 2026 /PRNewswire/ — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca’s pan-RAS molecular glue targeting solid tumors…
Source: prnewswire
Country: United States